Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

NCT03980080 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: OSE-127
DRUG: Placebo
DRUG: OSE-127

Sponsor

OSE Immunotherapeutics

Collaborators

[object Object]